Author

Yongli Yang

Observed name: Yong-li Yang

Institution: CStone Pharmaceuticals (China)

Observed institutions: Fudan University, Southwest Forestry University, Kunming Medical University, Shanghai Public Health Clinical Center, The First Hospital of Kunming, First Affiliated Hospital of Kunming Medical University, CStone Pharmaceuticals (China)

ORCID: 0000-0002-6271-0281

Observed ORCID: 0000-0002-6271-0281

OpenAlex ID: A5101982080

Soybean protein wood adhesive with enhanced water resistance and low environmental impact through lignin-protein hybridization

2025 · Yongli Yang, Haizhu Wu, et al. · Industrial Crops and Products · 17

Generation and characterization of a high‐affinity chimeric anti‐OX40 antibody with potent antitumor activity

2021 · Yongli Yang, Xiaojuan Chai, et al. · FEBS Letters · 6

Abstract 7299: CS2009: A first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFA with potential to be a next-generation backbone therapy with combined checkpoint inhibition and anti-angiogenesis

2025 · Chuan Wang, Ning Zhang, et al. · Cancer Research · 4

Abstract 2927: CS2011: A novel bispecific antibody targeting EGFR and HER3 that demonstrates promising antitumor activity in preclinical evaluation

2025 · Chuan Wang, Ning Zhang, et al. · Cancer Research · 1

Abstract 2954: CS5007: A novel EGFR and HER3 dual-targeted antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies

2025 · Chuan Wang, Yamin Wang, et al. · Cancer Research · 1

Abstract 4751: CS5005: A novel SSTR2-targeted antibody-drug conjugate (ADC) with robust antitumor activity in preclinical studies

2025 · Chuan Wang, Xinling Zhang, et al. · Cancer Research · 1

Abstract 1823: Preclinical efficacy and safety of CS5007, an EGFR×HER3 dual-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload.

2026 · Chuan Wang, Yamin Wang, et al. · Cancer Research

Abstract 1821: Preclinical efficacy and safety of CS5006, a novel integrin β4-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload.

2026 · Chuan Wang, Xinling Zhang, et al. · Cancer Research

Abstract 2953: CS5006: A novel integrin β4-targeted antibody-drug conjugate (ADC) with robust antitumor activity in preclinical studies

2025 · Chuan Wang, Yamin Wang, et al. · Cancer Research

504 CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluation

2024 · Chuan Wang, Ning Zhang, et al. · Journal for ImmunoTherapy of Cancer

The investigation of nursing needs of patients treated by PCI during pre - and post - operation

2009 · Jing Dai, Yong-li Yang, et al. · International journal of nursing

The nursing of catheterization

2009 · Yong-li Yang, Jinghua Zhang, et al. · International journal of nursing

Works count: 12

Citation count: 30

H-index: 3

I10-index: 1